Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Inclusion Criteria

• •MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone.
• •ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc).
• •Willing and able to provide written informed consent.
• •Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel.
• •Under the supervision of a physician for the current care of MF or ET.